Skip to content

Clinical efficacy of high-frequency repetitive transcranial magnetic stimulation in patients with severe stroke

Clinical efficacy of rTMS in the treatment of stroke patients and its association mechanism with serum inflammatory factor levels

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105502
Enrollment
Unknown
Registered
2025-07-04
Start date
2025-07-07
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

High-frequency group:Stimulation parameters of the low-frequency group: The stimulation site was the M1 area of the cerebral cortex on the healthy side, and the stimulation frequency was 1Hz
Low-frequency group:Stimulation parameters of the high-frequency group: cPMd was used as the target of stimulation in the high-frequency group, and the stimulation frequency was 5Hz
Control group:Stimulation parameters in the sham control group: The stimulation target and related parameters were the same as those in the high-frequency group, but the coil was rotated 90 degrees

Sponsors

Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Intracerebral Hemorrhage (2019) or the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2018), and be diagnosed by head CT or MRI examination; (2) Patients with initial or unilateral onset or previous seizures but no residual neurological dysfunction; (3) Stable vital signs and clear consciousness; (4) The patient's upper limb Brunnstrom grade was in stage I-IV; (5) Be between the ages of 18 and 75; (6) The course of the disease is between 2 weeks and 6 months; (7) Transcranial magnetic stimulation can measure the motor evoked potentials in the unaffected brain region; (8) The selected patients signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Upper limb movement disorder caused by other reasons before the onset of the disease; (2) Instability such as recurrent cerebral infarction or cerebral hemorrhage during hospitalization; (3) Severe audio-visual impairment, speech or cognitive impairment, unable to understand and cooperate with treatment and assessment; (4) History of skull fracture and/or severe head injury, head and/or brain surgery; (5) Those with transcranial magnetic contraindications: metal foreign bodies built into the skull, cardiac pacemaker installed, in-ear hearing aids, increased intracranial pressure, epilepsy or family history of epilepsy.

Design outcomes

Primary

MeasureTime frame
Fugl-Meyer Upper Extremity Motor Function Rating Scale;

Secondary

MeasureTime frame
Modified Barthel Index (MBI);Serologic evaluation;National Institutes of Health Stroke Scale;

Countries

China

Contacts

Public ContactYu Qian

Sichuan Provincial People's Hospitallun

13721518661@163.com+86 189 8183 8959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026